Table of contents

Clinical and epidemiological research

• The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal (17 March, 2009)

  M Rudwaleit, R Landewé, D van der Heijde, J Listing, J Brandt, J Braun, R Burgos-Vargas, E Collantes-Estevez, J Davis, B Dijkmans, M Dougados, P Emery, I E van der Horst-Bruinsma, R Inman, M A Khan, M Leirisalo-Repo, S van der Linden, W P Maksymowych, H Mielants, I Olivieri, R Sturrock, K de Vlam, J Sieper
• The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection (17 March, 2009) Free

  M Rudwaleit, D van der Heijde, R Landewé, J Listing, N Akkoc, J Brandt, J Braun, C T Chou, E Collantes-Estevez, M Dougados, F Huang, J Gu, M A Khan, Y Kirazli, W P Maksymowych, H Mielants, I J Sørensen, S Ozgocmen, E Roussou, R Valle-Oñate, U Weber, J Wei, J Sieper
• New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS) (15 January, 2009)

  J Sieper, D van der Heijde, R Landewé, J Brandt, R Burgos-Vagas, E Collantes-Estevez, B Dijkmans, M Dougados, M A Khan, M Leirisalo-Repo, S van der Linden, W P Maksymowych, H Mielants, I Olivieri, M Rudwaleit
• Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study (9 December, 2008)

  E C Keystone, M C Genovese, L Klareskog, E C Hsia, S T Hall, P C Miranda, J Pazdur, S-C Bae, W Palmer, J Zrubek, M Wiekowski, S Visvanathan, Z Wu, M U Rahman
• Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial (17 November, 2008)

  J Smolen, R B Landewé, P Mease, J Brzezicki, D Mason, K Luijtens, R F van Vollenhoven, A Kavanaugh, M Schiff, G R Burmester, V Strand, J Vencovský, D van der Heijde
• Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study (17 November, 2008)

  R Fleischmann, J Vencovsky, R F van Vollenhoven, D Borenstein, J Box, G Coteur, N Goel, H-P Brezinschek, A Innes, V Strand
• Impaired memory and learning abilities in patients with systemic lupus erythematosus as measured by the Rey Auditory Verbal Learning Test (1 July, 2008)

  D Paran, I Litinsky, I Shapira-Lichter, S Navon, T Hendler, D Caspi, E Vakil
• Vitamin D and chronic widespread pain in a white middle-aged British population: evidence from a cross-sectional population survey (12 August, 2008)

  K Atherton, D J Berry, T Parsons, G J Macfarlane, C Power, E Hyppönen
• Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade (1 July, 2008)

  J S Smolen, C Han, D M F M van der Heijde, P Emery, J M Bathon, E Keystone, R N Maini, J R Kalden, D Aletaha, D Baker, J Han, M Bala, E W St Clair, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group
• Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus (14 July, 2008)

  T L Rivera, P M Izmirly, B K Birnbaum, P Byrne, J B Brauth, M Katholi, M Y Kim, J Fischer, R M Clancy, J P Buyon
• Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies (15 July, 2008)

  O Kryštůfková, T Vallerskog, S Barbasso Helmers, H Mann, I Půtová, J Běláček, V Malmström, C Trollmo, J Vencovský, I E Lundberg
• Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies (14 July, 2008)

  W Kievit, J Fransen, E M Adang, H H Kuper, T L Jansen, C M A De Gendt, D J R A M De Rooij, H L M Brus, M A F J van de Laar, P C L M Van Riel
• Bone marrow lesions predict increase in knee cartilage defects and loss of cartilage volume in middle-aged women without knee pain over 2 years (14 July, 2008)

  A E Wluka, F Hanna, M Davies-Tuck, Y Wang, R J Bell, S R Davis, J Adams, F M Cicuttini
• Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database (14 July, 2008)

  U A Walker, A Tyndall, L Czirják, C P Denton, D Farge-Bancel, O Kowal-Bielecka, U Müller-Ladner, M Matucci-Cerinic, and the EUSTAR co-authors
• Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine (15 July, 2008)

  R Landewé, M Dougados, H Mielants, H van der Tempel, D van der Heijde
• Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients (17 July, 2008)

  C Popa, L J H van Tits, P Barrera, H L M Lemmers, F H J van den Hoogen, P L C M van Riel, T R D J Radstake, M G Netea, M Roest, A F H Stalenhoef
• Wegener’s granulomatosis patients show an adequate antibody response to influenza vaccination (14 July, 2008)

  A Holvast, C A Stegeman, C A Benne, A Huckriede, J C Wilschut, A M Palache, C G M Kallenberg, M Bijl
• Responsiveness of the International Classification of Functioning, Disability and Health (ICF) Core Set for rheumatoid arthritis (14 July, 2008)

  T Uhlig, R Moe, S Reinsberg, T K Kvien, A Cieza, G Stucki
• Evaluation of work-related psychosocial factors and regional musculoskeletal pain: results from a EULAR Task Force (22 August, 2008)

  G J Macfarlane, N Pallewatte, P Paudyal, F M Blyth, D Coggon, G Crombez, S Linton, P Leino-Arjas, A J Silman, R J Smeets, D van der Windt
• A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout (16 July, 2008)

  M K Reinders, C Haagsma, T L Th A Jansen, E N van Roon, J Delsing, M A F J van de Laar, J R B J Brouwers
• Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis (16 July, 2008)

  B Hoppe, T Häupl, K Egerer, R Gruber, H Kiesewetter, A Salama, G R Burmester, T Dörner
• The natural history of bone marrow lesions in community-based adults with no clinical knee osteoarthritis (3 August, 2008)

  M L Davies-Tuck, A E Wluka, Y Wang, D R English, G G Giles, F Cicuttini
• Obesity and adiposity are associated with the rate of patella cartilage volume loss over 2 years in adults without knee osteoarthritis (16 July, 2008)

  A J Teichtahl, A E Wluka, Y Wang, F Hanna, D R English, G G Giles, F M Cicuttini
• Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis (28 July, 2008)

  S M van der Kooij, Y P M Goekoop-Ruiterman, J K de Vries-Bouwstra, M Güler-Yüksel, A H Zwinderman, P J S M Kerstens, P A H M van der Lubbe, W M de Beus, B A M Grillet, H K Ronday, T W J Huizinga, F C Breedveld, B A C Dijkmans, C F Allaart
• Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial (13 August, 2008)

  D van der Heijde, M H Schiff, J Sieper, A J Kivitz, R L Wong, H Kupper, B A C Dijkmans, P J Mease, J C Davis, for the ATLAS Study Group
• Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group (1 October, 2008)

  M T Halpern, M A Cifaldi, T K Kvien
• Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI (23 July, 2008)

  J-P Raynauld, J Martel-Pelletier, P Bias, S Laufer, B Haraoui, D Choquette, A D Beaulieu, F Abram, M Dorais, É Vignon, J-P Pelletier, and the Canadian Licofelone Study Group
• Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index (4 June, 2008)

  W P Maksymowych, C Mallon, S Morrow, K Shojania, W P Olszynski, R L Wong, J Sampalis, B Conner-Spady
• Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate (19 May, 2008)

  G Wells, J-C Becker, J Teng, M Dougados, M Schiff, J Smolen, D Aletaha, P L C M van Riel
• Systemic sclerosis and its pulmonary complications in The Netherlands: an epidemiological study (29 May, 2008)

  M C Vonk, B Broers, Y F Heijdra, E Ton, R Snijder, A P J van Dijk, J M van Laar, H Bootsma, P Th W van Hal, F H J van den Hoogen, P L A van Daele
• Thoracoabdominal motion in ankylosing spondylitis: association with standardised clinical measures and response to therapy (16 July, 2008)

  G E Tzelepis, G Kalliakosta, A G Tzioufas, P P Sfikakis, C Mandros, K A Boki, C Roussos, H M Moutsopoulos
• Test–retest reliability of disease activity core set measures and indices in rheumatoid arthritis (28 October, 2008)

  T Uhlig, T K Kvien, T Pincus